Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methionine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | BHMT | Q93088 | 9/20 | 0.38 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racemethionine SCHEMBL4275749 | 1.00 | MEN1 (0.47) | MEN1KMT2ABHMTBHMT2LMNA | |
| Racemethionine SCHEMBL23924535 | 1.00 | MEN1 (0.47) | MEN1KMT2ABHMTBHMT2LMNA | |
| Racemethionine SCHEMBL9784232 | 0.96 | MEN1 (0.44) | MEN1KMT2ABHMTBHMT2LMNA | |
| Methionine SCHEMBL6248021 | 0.96 | MEN1 (0.44) | MEN1KMT2ABHMTBHMT2LMNA | |
| Methionine SCHEMBL3091904 | 0.95 | MEN1 (0.43) | MEN1KMT2ABHMTBHMT2LMNA | |
| Racemethionine SCHEMBL23924542 | 0.95 | MEN1 (0.43) | MEN1KMT2ABHMTBHMT2LMNA | |
| Methionine SCHEMBL4402781 | 0.95 | MEN1 (0.43) | MEN1KMT2ABHMTBHMT2LMNA | |
| D-Glutamate SCHEMBL20213749 | 0.94 | GRM8 (0.44) | MEN1KMT2ABHMTBHMT2LMNA | |
| Racemethionine SCHEMBL27639976 | 0.93 | MEN1 (0.42) | MEN1KMT2ABHMTBHMT2LMNA | |
| Methionine SCHEMBL8013049 | 0.92 | MEN1 (0.41) | MEN1KMT2ABHMTBHMT2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4983520-A | HEPATITIS VACCINE, ANTIGEN FOR DIAGNOSIS OF HEPATITIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-01-08 | — | — | US | claimed |
| US-20230320970-A1 | Skin Care Compositions | COLGATE-PALMOLIVE COMPANY (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4257113-A1 | SKIN CARE COMPOSITIONS COMPRISING VITAMIN E AND VITAMIN B3 | Colgate-Palmolive Company (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11759512-B2 | Modified norovirus VP1 proteins and VLPs comprising modified norovirus VP1 proteins | MEDICAGO INC. (CA) | 2023-09-19 | — | — | US | disclosed |
| EP-3932211-A1 | FUNCTIONAL COLLAGEN PROTEINS FOR PREPARING MEAT PRODUCTS | Paviso Alimentación, S.L. (ES) | 2022-01-05 | — | — | EP | disclosed |
| CN-113518784-A | Therapeutic peptides | 科巴公司 | 2021-10-19 | — | — | CN | disclosed |
| CN-113424897-A | Eucommia ulmoides leaf fermented feed and preparation method thereof | 贵州大学 | 2021-09-24 | — | — | CN | disclosed |
| EP-3821014-A1 | MODIFIED NOROVIRUS VP1 PROTEINS AND VLPS COMPRISING MODIFIED NOROVIRUS VP1 PROTEINS | Medicago Inc. (CA) | 2021-05-19 | — | — | EP | disclosed |
| US-20210128714-A1 | MODIFIED NOROVIRUS VP1 PROTEINS AND VLPS COMPRISING MODIFIED NOROVIRUS VP1 PROTEINS | MEDICAGO INC. (CA) | 2021-05-06 | — | — | US | disclosed |
| CN-110101787-B | Heart-clearing and depression-relieving powder, preparation method and application thereof | 张大志 | 2021-04-06 | — | — | CN | disclosed |
| EP-2729570-A2 | REAGENT USABLE FOR THE ISOLATION AND/OR PURIFICATION OF NUCLEIC ACIDS | Qiagen GmbH (DE) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013004710-A2 | REAGENT USABLE FOR THE ISOLATION AND/OR PURIFICATION OF NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2013-01-10 | — | — | WO | disclosed |
| US-7608459-B2 | Method for the determination of body odor | KAO CORPORATION (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20080175834-A1 | Carboxypertidase U (Cpu) Mutants | ASTRAZENCA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| US-20080014649-A1 | Method for the Determination of Body Odor | KAO CORPORATION (JP) | 2008-01-17 | — | — | US | disclosed |
| EP-1601974-A2 | DIFFERENTIAL MEGAPLEX IMMUNOASSAY | TCP Innovations Limited (GB) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004081025-A2 | DIFFERENTIAL MEGAPLEX IMMUNOASSAY | TCP INNOVATIONS LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
| US-4767748-A | Substituted oligosaccharide antibodies | SCHERING CORPORATION (US) | 1988-07-30 | — | — | US | disclosed |
| US-RE30473-E | ANTICONVULSANTS, MUSCLE RELAXANTS, SEDATIVES | HOFFMANN-LA ROCHE INC. (US) | 1981-01-06 | — | — | US | disclosed |
| US-4105852-A | ANTICONVULSANTS, MUSCLE RELAXANTS, SEDATIVES | HOFFMANN-LA ROCHE INC. (US) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230320970-A1 | Skin Care Compositions | TTPA, NQO1, ADH4 | MEN1 3544/4885KMT2A 3241/4885BHMT 111/4885 |
| US-20080014649-A1 | Method for the Determination of Body Odor | OR10J3, OR51E2, DRD4 | MEN1 1731/4885KMT2A 1503/4885BHMT 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.